CDSCO Panel Rejects Novo Nordisk Proposal to amend warning statement of Semaglutide Injection
New Delhi: Noting that post-marketing safety data in Indian patients is not presented, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has rejected Novo Nordisk's proposal for the amendment in the warning statement of Semaglutide Injection (0.25mg/0.5mg/1mg/1.7mg/2.4mg).
This came after Novo Nordisk India presented the proposal for amendment in the warning statement by including obstetricians, gynecologists, and bariatric surgeons.
Semaglutide injection is used along with a diet and exercise program to control blood sugar levels in adults with type 2 diabetes.
Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). GLP-1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.